Dr. Martens’ (DOCS) Buy Rating Reaffirmed at Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating reissued by equities research analysts at Berenberg Bank in a research note issued on Friday, Marketbeat Ratings reports. They currently have a GBX 110 target price on the stock. Berenberg Bank’s target price indicates a potential upside of 61.05% from the company’s current price.

Dr. Martens Price Performance

DOCS stock opened at GBX 68.30 on Friday. The stock has a market cap of £653.75 million, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26. The company has a quick ratio of 1.13, a current ratio of 2.61 and a debt-to-equity ratio of 108.85. Dr. Martens has a 52-week low of GBX 59.15 and a 52-week high of GBX 97.05. The business has a fifty day moving average of GBX 74.25 and a two-hundred day moving average of GBX 70.89.

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.